NCT06088017View on ClinicalTrials.gov

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

January 7, 2024

Study Completion Date

January 22, 2024

Conditions
Dyslipidemias
Interventions
DRUG

CKD-391(2)

QD, PO

DRUG

CKD-331, D337

QD, PO

Trial Locations (1)

07590

Bumin hopspital, Seoul, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT06088017 - A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2) | Biotech Hunter | Biotech Hunter